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Introduction
InfectIous diseases are caused by pathogenic microorganisms (e.g., bacteria, viruses, fungi and parasites) that must invade host cells in order to reproduce. these diseases are serious public health problems affecting 
a significant portion of the world’s population, and because of their socioeco-
nomic aspect represent a major challenge for the twenty-first century, especially 
in the poorest and most vulnerable regions of the planet. According to the 
World Health organization (WHo), infectious diseases account for about a 
third of the causes of death worldwide. the relationship between these diseases 
and the low income of the poorest populations is evidenced by the fact that 
infectious diseases rank first among the leading causes of death and permanent 
disability in developing countries (WHo, 2008).
Discovering and developing pharmaceutical drugs is a complex, lengthy 
and costly process, whose roots are deeply linked to scientific and technological 
innovations (Guido et al., 2008a). the significant advances in chemistry and bi-
ology and the better understanding of biochemical pathways, molecular targets 
and mechanisms that lead to the onset and progression of diseases have enabled 
the discovery of remarkable therapeutic innovations, providing significant im-
provements in the quality of life of many populations in the world.
Medicinal chemistry, which plays a recognized central role in drug R&D, 
is characterized by its relevant multidisciplinary nature, covering various spe-
cialties such as organic chemistry, biochemistry, pharmacology, information 
technology, and molecular and structural biology among others. According to 
the International union of Pure and Applied chemistry (IuPAc), medicinal 
chemistry is a discipline based on chemistry that involves the invention, discov-
ery, planning, identification, preparation and interpretation of the molecular 
mechanism of action of biologically active compounds. Besides the discovery 
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of bioactive molecules, medicinal chemistry also incorporates studies of the me-
tabolism and relationships between chemical structure and activity (Wermuth, 
2003). this clearly shows the establishment of key interfaces between chemical, 
biological, pharmaceutical, medical, physical and computational sciences.
Discovery and development of new pharmaceutical drugs
In the implementation of drug design strategies, studies of evolutionary 
processes of molecular recognition in biological systems are of great impor-
tance, since they set up the fundamental basis for understanding properties such 
as potency, affinity and selectivity. Given this complex paradigm, biotechnologi-
cal tools associated with medicinal chemistry methods play an outstanding role 
in the development of new molecules with biological activity.
the process of discovering and developing drugs, as shown in figure 1, is 
divided into two major phases: (i) discovery (also known as pre-clinical or basic 
research phase); and (ii) development (or clinical phase) (Lombardino & Lowe, 
2004). In the early stages of the discovery phase, research usually focuses on the 
identification and optimization of small molecules capable of representing new 
chemical entities (nce) with potential for clinical development. validation 
of the molecular target selected is essential for a number of reasons that range 
from establishing its relevance in the physiopathological process under study to 
characterizing the impact of its selective modulation in the treatment or cure of 
diseases or disorders in humans.
figure 1 – Phases involved in the discovery and development of pharmaceutical drugs 
(ADMe - absorption, distribution, metabolism and excretion; nDA - new 
drug application).
the three-dimensional (3d) structure of the selected biological target 
(e.g., protein, DnA or RnA) can be known or unknown, and this determines 
the prioritization of design strategies (Andricopulo et al., 2009). Great advances 
in genomics and proteomics, coupled with evolving X-ray crystallography and 
nuclear magnetic resonance (nMR) techniques provide a significant increase 
in the number of molecular targets with 3D structures available in the Protein 
Data Bank (PDB). 
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Bioactive molecules (or ligands) can be identified from actual (e.g., bio-
logical, biochemical) or virtual (e.g., computational) screenings of natural prod-
ucts, synthetic compounds or combinatorial collections, or by means of rational 
planning. It should be emphasized, however, that in all cases the biological 
properties must be determined experimentally, and the performance of stan-
dardized and validated high quality tests is essential. In general, low potency 
and affinity molecules are identified in the early design phases and should be 
optimized with respect to a series of pharmacodynamic (e.g., potency, affinity, 
selectivity) and pharmacokinetics (e.g., absorption, metabolism, bioavailability) 
properties. the optimized compounds are selected as lead compounds for fur-
ther development of a drug candidate (nce) (Guido & Andricopulo, 2008).
With the aid of medicinal chemistry methods it is possible to exploit the 
vast chemical space outlining the work involving the identification, selection 
and optimization of molecules capable of interacting, with high affinity and 
selectivity, with the selected molecular target (e.g., enzyme, receptor), which 
represents the biological space. several strategies can be used to investigate the 
chemical- biological space, such as: organization of databases, the use of mo-
lecular filters,  high-throughput screening and virtual screening.
Knowledge of the structures of macromolecular targets or of ligand-recep-
tor complexes enables structure-based drug design. In contrast, when the struc-
ture of the selected target is unknown, ligand-based drug design methods can be 
used, exploiting the properties and characteristics of series of bioactive ligands. In 
many cases, the use of integrated sBDD and LBDD strategies can generate use-
ful information for designing nce, through the synergy and complementarity of 
knowledge between the strategies (Guido et al., 2008a; Andricopulo et al., 2009). 
the skilled management of information is a very important factor in the present 
day, as it enables organizing and analyzing the vast amount of data available.
Biotechnology and drug discovery
the biotechnology revolution (e.g., genomics, functional genomics, pro-
teomics, metabolomics and cytomics) has provided extremely useful information 
for drug discovery. the suffix “omics” indicates a number of new disciplines and 
procedures aimed at the functional and/or structural identification of tissues, 
cells, gene expression patterns and metabolic characteristics (Bhogal & Balls, 
2008). these strategies have a variety of applications through the monitoring of 
biochemical or cellular indicators (e.g., transcription of a specific gene or varia-
tion in the expression/function of a particular protein), from the phase of iden-
tification of physiological and/or metabolic changes induced by the stage of the 
disease, to the evaluation of the effects of drugs in the human body (table 1). 
Although promising, these technologies have some limitations, including (i) the 
need for methods capable of interpreting and correlating in an optimized way 
the huge amount of information generated; and (ii) the rational and effective 
application of biological data in drug design.
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functional genomics (or transcriptome) focuses on the complete knowl-
edge of the set of transcripts (messenger RnA, ribosomal RnA, carrier RnA 
and microRnA) of a given organism, tissue or cell strain. functional genomics 
studies are based on microarray techniques capable of identifying and quantify-
ing mRnA transcripts in cells. the analysis of microarrays of RnA interference 
(RnAi) has contributed significantly to the evaluation of gene function through 
gene silencing or decreased expression of proteins (Mousses et al., 2003). How-
ever, post-translational events that are important for cellular regulation and sig-
naling, such as phosphorylation, glycosylation, membrane-anchoring and fold-
ing are rarely detected by this technique. Proteomic methods (Blackstock & 
Weir, 1999) are useful alternatives in these cases and, although less suitable for 
large-scale trials, provide more accurate and detailed data, since the strategies 
involved (e.g., mass spectroscopy) are based on the resolution and detection 
ability of specific proteins isolated from several sources.
Metabolomic studies allow the identification of low molecular weight me-
tabolites through very sensitive techniques such as nMR (Lindon & nicholson, 
2008), which requires only 20 mg of tissue or biofluids (Bollard et al. 2005). In 
addition, the procedures involved can be widely applied in studies to evaluate 
pharmacokinetic properties of drug candidates, both in the preclinical phase in 
animal models and in human clinical trials (figure 2). the use of the Human 
Metabolome Database) (Wishart et al., 2007) assists in the evaluation of the 
impact of diseases on the metabolism of different organisms.
cytomics, which is characterized by the study of cellular systems, is based 
on a less reductionist assumption that integrates data from functional genomics 
and metabolomics to elucidate genetic and biochemical events in a single cell 
(valet, 2006). techniques previously exclusive to cellular studies, such as flow 
cytometry, confocal microscopy, bioimaging and fluorescence are being applied 
in drug R&D because they allow data collection in real time, showing a realistic 
scenario of the biological phenomena.
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table 1 – Biotechnological strategies and methods
Strategy Sample Technology Information Advantages Limitations
Genomics DNA DNA Sequencing Nucleotide se-
quence 
Efficiency in data 
generation 
Excessive data 
generation
Functional 
genomics
RNA Determination of 
transcripts - mRNA
mRNA hybridiza-
tion patterns 
Efficiency in data 
generation
Extrapolation of 
mRNA transcript 
to protein expres-
sion
Proteomics Proteins Mass spectroscopy, 
gel electrophoresis, 
protein chips, anti-
body arrays
Amino acid se-
quence, post-trans-
lational changes, 
interactions be-
tween proteins
Data generated 
on a medium-
scale; relevant 
information for 
discovering new 
targets
Low efficiency in 
data generation, as-
sociated noise
Metabolo-
mics
Metabolites Mass spectroscopy, 
NMR, HPLC
Metabolite mol-
ecules 
High-scale 
screening with 
significant trans-
fer capability for 
studies
Complex mixtures, 
associated noise, 
reproducibility
Cytomics Cells Digital imaging, 
fluorescence, immu-
nohistochemistry
Photons Optimization of 
temporal and spa-
tial visualization 
of cellular effects 
of drugs
Difficulty in ob-
taining relevant 
biomarkers
In general, the different biotechnological strategies discussed produce 
large amounts of data that need be analyzed quickly and effectively. In this con-
text, bioinformatics methods play a key role by enabling the organization, man-
agement, visualization and interpretation of the information generated. the 
goal is the establishment of correlation patterns between different biochemical 
and cellular events involved in the disease state (or during treatment with a drug 
candidate). the integrated analysis of these data leads to interactomics (cusick 
et al., 2005), which is characterized by the mapping of interaction networks 
among the various biological phenomena (e.g., molecular, biochemical, cellu-
lar). A significant number of data containing maps of the interaction of various 
biological systems is available in databases accessible to the public, such as: (i) 
PsI-MAP - Protein structural Interactome Map (Gong et al., 2005); (ii) DIP 
- Database of Interacting Proteins (Xenarios et al., 2000); ( iii) BInD - Bio-
molecular Interaction network Database (Bader et al., 2003); and (iv) MInt 
- Molecular Interaction Database) (Zanzoni et al., 2002).
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figure 2 – Integration of biotechnology in drug R&D.                    
Neglected tropical diseases 
neglected tropical diseases (ntD) are striking consequences of social 
underdevelopment, depicting in detail the situation of the poorest and most 
disadvantaged regions on the planet (Beyrer et al., 2007). ntD are endemic in 
several important geographic regions (Dias et al., 2009), affecting millions of 
people and determining high morbidity and mortality rates. for the majority 
of priority ntD in WHo special programs (e.g., malaria, African trypanoso-
miasis (sleeping sickness), American trypanosomiasis (chagas’ disease), dengue 
fever, leprosy, leishmaniasis, schistosomiasis, and onchocerciasis, among others), 
the therapeutic options are inadequate and pose a number of problems such as 
low effectiveness, high toxicity and the emergence of resistant strains (Guido 
& oliva, 2009). this scenario is compounded by the limited number and lack 
of innovation in drug R&D programs in the area of  ntD (nwaka & Hudson, 
2006; nwaka et al., 2008). thus, the situation calls for concentrated global ef-
forts (government - academia - industry) for the creation and maintenance of 
R&D programs aimed at the discovery of new alternative therapies for the treat-
ment and control of these diseases (Guido & oliva, 2009).
the WHo special Program for Research and training in tropical Diseas-
es (tDR), the Medicines for Malaria venture (MMv) Program and the Drugs 
for neglected Diseases Initiative (DnDi) are examples of public-private part-
nerships that aim to create, stimulate and invest in R&D of drugs against a va-
riety of ntD (Dias et al. 2009). some examples of drugs that have reached the 
market through public-private partnerships are provided in table 2.
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table 2 – Anti-Dtn drugs developed through public-private partnerships 
Drug Registry Therapeutic 
Indication 
Pubic-private 
partnerships
Praziquantel 1976 Schistosomiasis Bayer / TDR
Mefloquine 1984 Malaria Hoffman La Roche / Wrair* 
/ TDR
Ivermectin 1987 Onchocerciasis Merck / TDR
Halofantrine 1988 Malaria Smith Kline Beecham, Wrair* 
/ TDR
Eflornithine 1991 Sleeping sickness Marion Merrel Dow / TDR
Liposomal Amphotericin B 1994 Leishmaniasis NeXstar / TDR
Artemisinin 1997 Malaria Rhone Poulenc Rorer / 
Kunming / TDR
Artemisinin-lumefantrine 1999 Malaria Novartis / Chinese 
government
Artemotil 2000 Malaria Artecef / WRAIR / TDR
Miltefosine 2002 Leishmaniasis Zentaris, Indian CMR / TDR
Artesunate-amodiaquine 2007 Malaria Sanofi-Aventis / DNDi
Artesunate-mefloquine 2008 Malaria Farmaguinhos / DNDi
* WRAIR - Walter Reed Army Institute of Research.
National R&D initiatives in the area of NTD
extremely important initiatives are being successfully implemented to 
include Brazil in an increasingly significant science and technology scenario. 
three examples are presented to illustrate the breadth and diversity of networks 
and partnerships that have provided great opportunities and challenges in the 
area of  ntD.
the center for structural Molecular Biotechnology (cBMe) is the result 
of solid collaborations established in drugs R&D projects involving: (i) Pro-
tein crystallography and structural Biology and Medicinal and computational 
chemistry Laboratories (LQMc) of the Institute of Physics of são carlos uni-
versity in são Paulo (Ifsc-usP); (ii) the national synchrotron Light Laborato-
ry (LnLs) in campinas; and (iii) the chemistry (DQ), Genetics and evolution 
(DGe) and Physiological sciences (Dcf) departments of the federal university 
of são carlos (ufscar). the cBMe is one of the ten Research, Innovation and 
Dissemination centers (cePID) supported by the são Paulo Research foun-
dation (fAPesP) (cBMe, 2010). the main objectives of the cBMe include 
conducting basic and applied research, generating scientific and technological 
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innovation, and disseminating knowledge and education in all areas of biotech-
nology. to meet its objectives, the cBMe has adopted an integrated multidis-
ciplinary approach, which includes the use of molecular biology, biochemistry, 
organic chemistry, structural biology and medicinal chemistry methods.
the research projects of the cBMe have as a common link a molecular 
approach that entails exploring complex biological systems of great importance 
to sensitive areas of our society, such as pharmaceutical drugs and medicines, 
agribusiness and biotechnology. one of the major goals of the cBMe is to 
achieve maximum integration with the productive sector, particularly with na-
tional and multinational pharmaceutical industries, biotechnology companies, 
and research institutions on human health, among others, for the establishment 
of partnerships and/or other forms of cooperation in drug R&D. In short, 
in the last ten years the cBMe has spearheaded innovative projects in struc-
tural biotechnology and medicinal chemistry, including patent development 
and technology transfer. the dissemination of science and knowledge achieved 
through programs dedicated to secondary school students and teachers as well 
as to the general population also deserve special mention.
the national Institute of structural Biotechnology and Medicinal chem-
istry in Infectious Diseases (InBeQMeDI) is another successful example 
of integrated multidisciplinary initiative focused on the development of new 
drug candidates using specific molecular targets in microorganisms associated 
with infectious diseases. the InBeQMeDI was established under the Mct/
cnPq/Ms/fAPesP program of national Institutes of science and technolo-
gy (Inct). this program has ambitious and far-reaching goals in national terms 
as a possibility for mobilizing and aggregating, in a coordinated fashion, the best 
research groups in frontier areas of science and strategic areas for the sustainable 
development of the country; boosting competitive basic and fundamental scien-
tific research internationally; stimulating the development of advanced scientific 
and technological research associated with applications aimed to promote inno-
vation and entrepreneurship, in close collaboration with innovative companies, 
among others (InBeQMeDI, 2010a).
the InBeQMeDI is an offshoot of the successful  “cBMe/cePID/
fAPesP” initiative and is headquartered at the Institute of Physics of são car-
los, university of são Paulo. It also includes associated groups from the chem-
istry Department of the federal university of são carlos (DQ-ufscar), the 
Institute of Biosciences (IB-usP), the Institute of Biological sciences (IcB-
usP), the school of Medicine of Ribeirão Preto (fMRP-usP), and two groups 
of young researchers from the state university of Ponta Grossa (uePG) and 
the federal university of viçosa (ufv). the approaches used are based on 
modern structural biotechnology and medicinal chemistry. the action strate-
gy of the InBeQMeDI is to conduct both basic and applied research and to 
promote technological development and the dissemination of education in the 
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area of ntD. to achieve these goals, the InBeQMeDI has been promoting 
a multidisciplinary approach, including the use of methods of molecular biol-
ogy, biochemistry, structural biology (protein crystallography, multidimensional 
nMR, molecular modeling and bioinformatics), medicinal chemistry based on 
products of natural and  synthetic origin, drug design, molecular immunology, 
cell biology and pharmacology (InBeQMeDI, 2010b).
As a last example, it is worth noting that our group has been selected by 
the World Health organization (WHo), in its special Program for Research and 
training in tropical Diseases - tDR/WHo-unIcef/unDP/World Bank - 
Business Line on Lead Discovery for Infectious tropical Diseases - new Medici-
nal chemistry centers to Join Drug Discovery networks, as a Reference center 
in Medicinal chemistry for chagas’ disease. our WHo center aims basically to 
advance the development of new drug candidates for the treatment of chagas’ 
disease. Research activities involve effective integration with partner laboratories 
in the WHo network of medicinal chemistry, including large pharmaceutical 
companies like Pfizer, Merck, and chemtura and Pharmacopeia (WHo, 2010).
Molecular targets for drug discovery 
enzymes are extremely important biological targets for the design of nov-
el drugs, because of their essential role in biochemical pathways associated with 
human diseases and disorders. other attractions include the fact that they are 
usually easy to obtain, are suitable for biological trials and versatile in the ap-
plication of sBDD and LBDD techniques (Mestres, 2005). enzyme inhibitors 
of the reversible type are the most studied drug candidates and can be classified 
as competitive and uncompetitive. there are also the irreversible enzyme inac-
tivators, which act especially as affinity labels or mechanism-based inactivators, 
leading to covalent modification of the enzyme (copeland, 2005).
According to data from the u.s. food and Drug Administration (fDA), 
approximately 25 percent of registered nce (317 out of 1278 nce) had as 
targets 71 enzymes from five different sources (figure 3) (Robertson, 2005).
Examples of use of drug design methods
one of the great challenges of medicinal chemistry in the drug design pro-
cess is to contribute to increase the success rate in the discovery of nces. the 
integration of experimental and computational methods is of great importance 
in the identification and development of new bioactive molecules from real or 
virtual compound collections. In this context, sBDD and LBDD strategies 
gain natural highlight (Andricopulo et al., 2009). sBDD methods are based on 
knowledge of the topological array of biological targets, and therefore use as a 
prerequisite detailed 3D data on the macromolecule under study. this informa-
tion can be obtained through the analysis of crystallographic structures, nMR 
or homology modeling. Molecular docking is one of the main sBDD strategies, 
and consists in the prediction of the bioactive conformation of a small molecule 
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(ligand) in the binding site of a macromolecule (target protein), followed by the 
evaluation (scoring) and classification of the proposed binding mode. structure-
based virtual screening (sBvs) uses molecular docking methods in the analysis 
of large databases of compounds, with the aim of characterizing a privileged 
chemical-biological space and enable the selection of compounds for  biochemi-
cal and/or biological tests (Guido et al. 2008a; Andricopulo et al. 2009).
figure 3 –  enzymes as molecular targets of fDA-approved drugs (Robertson, 
2005).
the design of antiparasitic drugs is based primarily on the investigation of 
biochemical pathways of the parasite and, where appropriate, on the comparison 
of these with that of the host, with the aim to identify possible targets for selec-
tive modulation by small molecules (verlinde et al., 2001). the use of modern 
medicinal chemistry strategies can be seen in the example of purine nucleoside 
phosphorylase of Schistosoma mansoni (smPnP), a key enzyme in the purine 
rescue pathway (Postigo et al. 2010). In this study, the active smPnP site was 
selected as a target for the development of a 3D pharmacophore model, which 
was used in the virtual screening of a large database, leading to the identification 
of three thioxothiazolidine derivatives with in vitro activity against the target 
enzyme (figure 4a). subsequently, the integration between molecular design, 
organic synthesis and biological evaluation was instrumental in the process that 
resulted in the identification of a series of twenty thioxothiazolidine derivatives, 
enabling the establishment of structure-activity relationships (sAR). It is worth 
emphasizing that the molecular optimization process resulted in the discovery 
of a lead compound (figures 4B and 4c) with potency approximately twenty 
times greater than its precursors.
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figure 4 – (A) molecular structure of the compounds selected in the vs. (B) Lead 
compound identified. (c) Binding mode of smPnP inhibitors identi-
fied through sBDD strategies. the enzyme is represented by the ribbon 
model and the active site is indicated by the solvent accessible surface. 
the pharmacophore model is indicated by spheres that define the areas fa-
vorable for hydrogen bond acceptor/donor groups (magenta); hydrogen 
bond donor groups (blue); and hydrophobic groups (orange). the lead 
compound (yellow) and one of the thioxothiazolidines (pink) are repre-
sented as stick models.
Besides its importance in the identification of new modulators (i.e., re-
ceptor ligands or small molecules with biological activity), medicinal chemistry 
studies are useful in the development of a drug candidate nce. In this regard, 
special mention should be made of the QsAR (quantitative structure-activity 
relationships) methods, whose goals are to relate the information in data sets 
(chemical structure, properties and biological activity) and create statistical 
models with external predictive ability. therefore, they are extremely valuable 
for designing molecules with improved properties (pharmacodynamic and phar-
macokinetic) compared to those of the original data set used in the molecular 
modeling (salum & Andricopulo, 2009, 2010; fashion et al., 2007). However, 
it should be noted that QsAR studies require careful standardization in crucial 
aspects such as: (i) the molecules from the data set should be chemically related; 
(ii) the biological parameter should be quantitative and obtained under the same 
experimental conditions for all members of the data set; and (iii) all compounds 
in the series should work in a single molecular target in the same binding cavity 
and through the same mechanism of action (farutin et al. 1999); (iv) the statis-
tical method should be appropriate to the level of information available, so that 
the generated model can provide useful information for the molecular design 
(salum & Andricopulo, 2009, 2010). the cyclic process of data generation, the 
construction of QsAR and property prediction models evolves to the synthesis 
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and biological evaluation of new molecules, resulting in the discovery of nce 
that are candidates for clinical studies.
Another option widely explored when 3D structures of macromolecular 
targets are available is integrating the QsAR and sBDD methods. for example, 
once the chemical and structural characteristics associated with the biological 
property are identified in the QsAR modeling, these can be compared with the 
information obtained from the 3D topology of the receptor in question. Hence 
the complementary essence of the methods and their importance as a drug de-
sign strategy (trossini et al., 2009).
the integration of the QsAR and sBDD methods can be observed in 
studies conducted with a series of glyceraldehyde 3-phosphate dehydrogenase 
enzyme inhibitors (GAPDH), an attractive molecular target for the develop-
ment of drugs against trypanosomiasis (Guido et al. , 2008b). the data set used 
to generate the 3D predictive QsAR models consisted of 70 adenosine deriva-
tives (figure 5a), which were designed based on significant structural differ-
ences between the active sites of Leishmania mexicana enzymes and its human 
homologue. the molecular properties were quantitatively related to inhibitory 
potency, using methods of comparative molecular field analysis (coMfA) (cra-
mer et al., 1988) and comparative molecular similarity indices analysis (coM-
sIA) (Klebe et al. 1994). these methods consider that the biological activity of 
a data set is directly related to intermolecular interactions prevailing in the mo-
lecular recognition and binding affinity process, i.e., the stereo-electronic inter-
actions (non-covalent) involved in the formation of the drug-receptor complex 
type. Because of their 3D character, molecular interaction fields (MIf) are used 
as descriptors. Another striking feature is the study of bioactive conformations 
and the 3D structural alignment (orientation in cartesian space) of molecules 
from the dataset.  for that purpose, this study used molecular docking methods 
to obtain the molecular alignment of inhibitors in the binding site of enzyme 
LmGAPDH (figure 5B). coMfA and coMsIA models with high internal (cor-
relation) and external (prediction) consistency were generated, indicating their 
usefulness in the design of new more potent and selective inhibitors (figure 
5c). An additional feature of the 3D QsAR methods is to enable visualization 
of regions in the space that can be directly related to biological property (figure 
5D). the detailed analysis of contour maps enabled elucidating the structural 
bases involved in the molecular recognition process, as well as in the potency 
and selectivity of the inhibitors investigated, evidencing, therefore, the comple-
mentary nature of and synergy between the QsAR and sBDD methods.
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figure 5 – (A) General structure of the series of adenosine-derived LmGAPDH inhib-
itors. (B) structural alignment of the 70 inhibitors used in QsAR model-
ing. the compounds are represented as rod models in the LmGAPDH 
active site, indicated by the solvent accessible surface. (c) Generation of 
coMfA models with high internal and external consistency. (D) contour 
maps of the main  stereo-electronic characteristics of the dataset. the most 
potent (light blue), and less potent (orange) inhibitors are shown in the 
protein binding cavity. contour maps (i) stereo: favorable in green, unfa-
vorable in yellow; and (ii) electrostatic: favorable in blue, unfavorable in 
red.
Another interesting example of the integration of experimental and com-
putational methods, particularly of enzyme kinetics and molecular modeling can 
be seen in the study of a series of chalcones with activity against Mycobacterium 
tuberculosis tyrosine phosphatase A (MtPtpA) (figure 6A), a biomolecule that 
plays a central role in the processes of cell signaling and invasion in mycobacteria 
(Mascarello et al., 2010). In this study, quantitative parameters such as potency 
(Ic50, inhibitor concentration required to reduce enzymatic activity by 50 per-
cent) and affinity (Ki, inhibition constant) were determined experimentally and 
the   mechanism of action was clarified. Briefly, enzyme kinetic studies have 
indicated a reversible mechanism of the competitive type for chalcones, with 
Ki values  in the low micromolar range (figure 6B). Based on this information, 
molecular modeling studies have been conducted to evaluate the mode of inter-
action of inhibitors against the target enzyme and identify the structural basis 
responsible for the molecular recognition process. the models indicated the 
critical role of hydrogen bonding and π-electron interactions between chemical 
functionalities of the ligands (substituents of the phenyl group and naphthyl ar-
omatic system) and amino acid residues from the active site of MtPtpA (thr12, 
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Arg17, His49 and trp48, figure 6c). subsequently, in vitro and in vivo studies 
demonstrated both the low toxicity of synthetic chalcones and their ability to 
prevent intracellular survival and proliferation of mycobacteria, suggesting the 
potential of this class for the development of new drug candidates for the treat-
ment of tuberculosis.
Figure 6 – (a) Series of chalcones with potent inhibition activity against MtPtpA. (B) 
Lineweaver-Burk double-reciprocal plots for the competitive inhibition mech-
anism. (C) Molecular modeling and studies of the mode of interaction of in-
hibitors. The active MtPtpA site is indicated by the solvent accessible surface, 
inhibitors as rod models and hydrogen bonds as dashed lines.
Conclusion
scientific and technological advances in the interfaces between chemistry 
and biology have provided remarkable opportunities and challenges in drug 
R&D, with a great emphasis on two fundamental components: innovation 
and integration, which translate very well the central role of modern medicinal 
chemistry. Drug R&D has grown at a fast pace in Brazil. this trend should 
increase sharply through investments in infrastructure, personnel qualification 
and research, thus encouraging a more balanced regional development and the 
strengthening of partnerships between university, government and industry. 
Looking to the future requires a strategic perspective of continuity. creativity 
and boldness are essential to understand and anticipate new opportunities. the 
common commitment is to integrate actions, participate and contribute in the 
best way possible to the advancement of scientific knowledge and technological 
expertise. It is essential to combine organized efforts, coordinate strategies for 
attracting financial, human and material resources, consolidate ideas and find 
new solutions that will ensure, in the coming decades, Brazil’s evolution from 
an emerging nation to a world power in the area of drugs and medicines.
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abstRaCt – current drug design strategies are based on the understanding of the physio-
pathology of diseases, biochemical pathways and selection of molecular targets. Modern 
biotechnological tools have provided valuable information to facilitate the discovery of 
new drug candidates. Medicinal chemistry has a vital role in a variety of processes aimed 
at the identification of bioactive substances and the development of lead-compounds 
with optimized  pharmacodynamic and pharmacokinetic properties.  the present  paper 
presents some fundamental  aspects of biotechnology and medicinal chemistry as useful 
tools in the design of new chemical entities for the therapy of infectious diseases.
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